Skip to search formSkip to main contentSkip to account menu

Bexxar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
There is a long history of absorbed dose calculations being performed to evaluate the risks involved in the application of… 
Review
2007
Review
2007
Currently, beta-emitting radionuclides are used almost exclusively in the clinic and in clinical radioimmunotherapy studies. The… 
2007
2007
Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had… 
2007
2007
8089 Background: BTR has demonstrated efficacy in NHL patients and it has potential to prolong time to progression (TTP) in… 
2005
2005
Advanced follicular lymphomas (FL) are incurable with conventional chemotherapy regimens. The Southwest Oncology Group… 
2004
2004
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial… 
2004
2004
6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory… 
2004
2004
Waldenstrom's macroglobulinemia is an indolent B-cell malignancy that is characterized by high levels of IgM paraprotein… 
2002
2002
Radioimmunotherapy (RIT) with Bexxar (tositumomab and iodine‐131 tositumomab; Coulter Pharmaceutical, South San Francisco, CA…